FC
Frank Czerwiec
Endocrinology, Diabetes & Metabolism
Credentials: ·
Research
Tolvaptan in patients with autosomal dominant polycystic kidney disease
New England Journal of Medicine · 2012 · 1,273 citations
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia
New England Journal of Medicine · 2006 · 881 citations
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
New England Journal of Medicine · 2017 · 505 citations
26 papers
23 papers
21 papers
- JG
6 papers
4 papers
4 papers
3 papers
- MG
3 papers
